Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

10.0%

2 terminated/withdrawn out of 20 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

25%

5 trials in Phase 3/4

Results Transparency

106%

17 of 16 completed trials have results

Key Signals

17 with results

Enrollment Performance

Analytics

Phase 1

10(50.0%)

Phase 2

4(20.0%)

Phase 3

4(20.0%)

N/A

1(5.0%)

Phase 4

1(5.0%)

20Total

Phase 1(10)

Phase 2(4)

Phase 3(4)

N/A(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials

NCT04689932Phase 4Completed

Triferic AVNU Infusion Via Freedom Pump During Hemodialysis

Role: lead

NCT05110768Phase 2Unknown

Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy

Role: lead

NCT04409132Phase 1Completed

Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.

Role: lead

NCT04239391Phase 3Unknown

Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)

Role: lead

NCT04042324Phase 1Completed

A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

Role: lead

NCT00548249Phase 2Completed

Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis

Role: lead

NCT03303144Phase 1Completed

Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Role: lead

NCT02905981Phase 2Terminated

Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol

Role: lead

NCT02636049Phase 1Completed

Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers

Role: lead

NCT02909153Phase 1Completed

Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis

Role: lead

NCT02767128Phase 1Completed

Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers

Role: lead

NCT02739100Phase 1Completed

Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Role: lead

NCT02595437Phase 1Completed

Triferic Pediatric Pharmacokinetic Protocol

Role: lead

NCT01286012Phase 2Completed

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

Role: lead

NCT01322347Phase 3Completed

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)

Role: lead

NCT01320202Phase 3Completed

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

Role: lead

NCT01503021Phase 3Completed

Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis

Role: lead

NCT00604565Not ApplicableTerminated

Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients

Role: collaborator

NCT01894906Phase 1Completed

Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients

Role: lead

NCT01920854Phase 1Completed

A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.

Role: lead

All 20 trials loaded